BAYP:OTC-Bayport International Holdings, Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | OTC

Last Closing Price

USD 0.80

Change

0.00 (0.00)%

Market Cap

USD 10.85B

Volume

2.39K

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Bayport International Holdings, Inc. engages in the acquisition and mining of oil and gas properties in the United States. The company is also involved in the acquisition and exploitation of mining properties, primarily precious metals, and rare earth and other metals. It holds interests in various oil and gas properties, including Wayne Prospect located in Wayne County, West Virginia; Brown Well lease in Macintosh County, Oklahoma; Steffelbeam lease in Forrest County, Pennsylvania; and Milford lease located in Forest County, Pennsylvania, as well as owns interests in the wells located within Gaines County, Texas. The company was formerly known as Exit Only, Inc. and changed its name to Bayport International Holdings, Inc. in 2012. Bayport International Holdings, Inc. was founded in 2004 and is headquartered in Dallas, Texas.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-20 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MKGAF MERCK Kommanditgesellschaft au..

N/A

USD80.36B 29.16 17.26
MKKGY MERCK Kommanditgesellschaft au..

N/A

USD79.39B 28.51 17.26
TKPHF Takeda Pharmaceutical Company ..

N/A

USD54.07B 15.78 0.07
ESALY Eisai Co., Ltd

N/A

USD31.03B 81.65 0.19
ESALF Eisai Co., Ltd

N/A

USD29.49B 76.17 0.19
SFOSF Shanghai Fosun Pharmaceutical ..

N/A

USD23.06B 29.29 4.17
SGIOY Shionogi & Co., Ltd

N/A

USD15.39B 15.49 0.07
SGIOF Shionogi & Co., Ltd

N/A

USD15.14B 15.25 0.07
TEVJF Teva Pharmaceutical Industries..

N/A

USD11.26B 900.00 16.02
MTZPY Mitsubishi Tanabe Pharma Corpo..

N/A

USD10.43B 79.00 0.21

ETFs Containing BAYP

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -20.00% 19% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -20.00% 19% F 13% F
Trailing 12 Months  
Capital Gain -20.00% 25% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -20.00% 25% F 12% F
Trailing 5 Years  
Capital Gain -20.00% 39% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -20.00% 39% F 29% F
Average Annual (5 Year Horizon)  
Capital Gain 49.39% 64% D 72% C-
Dividend Return N/A 24% F 53% F
Total Return 49.39% 64% D 72% C-
Risk Return Profile  
Volatility (Standard Deviation) 821.96% 13% F 11% F
Risk Adjusted Return 6.01% 41% F 29% F
Market Capitalization 10.85B 97% A+ 89% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio N/A N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -0.72% 61% D- 45% F
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 122.94 1% F 1% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.